Iterion Therapeutics
PrivateLast Round
Grant
Feb 16, 2022
Total Funding Raised
$41.91M
Momentum Score
50 /100
Company Overview
Iterion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel targeted cancer therapeutics. Its lead product, tegavivint, is a first-in-class small molecule inhibitor of Transducin Beta-like Protein 1 (TBL1), a newly characterized downstream target in the Wnt/beta-catenin signaling pathway. By binding to TBL1, tegavivint disrupts the complex that activates cancer-causing genes, promoting the degradation of nuclear beta-catenin. The company is actively enrolling patients in clinical trials to evaluate tegavivint in various cancers with high unmet needs, including advanced hepatocellular carcinoma (HCC) and certain types of lymphomas. Iterion Therapeutics was formerly known as Beta Cat Pharmaceuticals and was founded in 2010.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2G
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Iterion Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Iterion Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 16, 2022 | ||||
| Series B | Feb 16, 2021 | ||||
| Series B | Dec 5, 2018 | ||||
| Grant | Feb 19, 2014 |
Iterion Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GOOSE Capital | Series B |
| GPG Ventures | Series B |
| Viva BioInnovator | Series B |
| Venture Investors LLC | Series B |
| Lumira Ventures | Series B |
| angelMD | Series B |
Iterion Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Iterion Therapeutics's valuation, stock price, and market status.
